Hisashi Oishi1, Tatsuaki Watanabe2, Yasushi Matsuda2, Masafumi Noda2, Yutaka Ejima3, Yoshikatsu Saiki4, Kuniaki Seyama5, Takashi Kondo6, Yoshinori Okada2. 1. Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan. hisashi.oishi.c7@tohoku.ac.jp. 2. Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan. 3. Department of Anesthesiology, Tohoku University Hospital, Sendai, Japan. 4. Department of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. 5. Division of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, Japan. 6. Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Abstract
PURPOSE: Lung transplantation is accepted as an effective modality for patients with end-stage pulmonary lymphangioleiomyomatosis (LAM). Generally, bilateral lung transplantation is preferred to single lung transplantation (SLT) for LAM because of native lung-related complications, such as pneumothorax and chylothorax. It remains controversial whether SLT is a suitable surgical option for LAM. The objective of this study was to evaluate the morbidity, mortality and outcome after SLT for LAM in a lung transplant center in Japan. METHODS: We reviewed the records of 29 patients who underwent SLT for LAM in our hospital between March, 2000 and November, 2017. The data collected included the pre-transplant demographics of recipients, surgical characteristics, complications, morbidity, mortality and survival after SLT for LAM. RESULTS: The most common complication after SLT for LAM was contralateral pneumothorax (n = 7; 24.1%). Six of these recipients were treated successfully with chest-tube placement and none required surgery for the pneumothorax. The second-most common complication was chylous pleural effusion (n = 6; 20.7%) and these recipients were all successfully treated by pleurodesis. The 5-year survival rate after SLT for LAM was 79.5%. CONCLUSION: LAM-related complications after SLT for this disease can be managed. SLT is a treatment option and may improve access to lung transplantation for patients with end-stage LAM.
PURPOSE: Lung transplantation is accepted as an effective modality for patients with end-stage pulmonary lymphangioleiomyomatosis (LAM). Generally, bilateral lung transplantation is preferred to single lung transplantation (SLT) for LAM because of native lung-related complications, such as pneumothorax and chylothorax. It remains controversial whether SLT is a suitable surgical option for LAM. The objective of this study was to evaluate the morbidity, mortality and outcome after SLT for LAM in a lung transplant center in Japan. METHODS: We reviewed the records of 29 patients who underwent SLT for LAM in our hospital between March, 2000 and November, 2017. The data collected included the pre-transplant demographics of recipients, surgical characteristics, complications, morbidity, mortality and survival after SLT for LAM. RESULTS: The most common complication after SLT for LAM was contralateral pneumothorax (n = 7; 24.1%). Six of these recipients were treated successfully with chest-tube placement and none required surgery for the pneumothorax. The second-most common complication was chylous pleural effusion (n = 6; 20.7%) and these recipients were all successfully treated by pleurodesis. The 5-year survival rate after SLT for LAM was 79.5%. CONCLUSION: LAM-related complications after SLT for this disease can be managed. SLT is a treatment option and may improve access to lung transplantation for patients with end-stage LAM.
Entities:
Keywords:
Chylous pleural effusion; Lymphangioleiomyomatosis; Pneumothorax; Single lung transplantation
Authors: Roger D Yusen; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Samuel B Goldfarb; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Joseph W Rossano; Josef Stehlik Journal: J Heart Lung Transplant Date: 2015-09-03 Impact factor: 10.247
Authors: T Ito; M Suno; K Sakamoto; Y Yoshizaki; K Yamamoto; R Nakanishi; Y Hirano; M Irie; T Kurosaki; S Otani; M Yamane; S Sugimoto; K Miyoshi; T Oto Journal: Transplant Proc Date: 2016 Jan-Feb Impact factor: 1.066
Authors: Christian Benden; Federico Rea; Jürgen Behr; Paul A Corris; Martine Reynaud-Gaubert; Marc Stern; Rudolf Speich; Annette Boehler Journal: J Heart Lung Transplant Date: 2009-01 Impact factor: 10.247
Authors: Gabriel Thabut; Jason D Christie; Philippe Ravaud; Yves Castier; Olivier Brugière; Michel Fournier; Hervé Mal; Guy Lesèche; Raphaël Porcher Journal: Lancet Date: 2008-03-01 Impact factor: 79.321
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569